A Phase 4 interventional study of Inclisiran Sodium and Placebo in Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 136 sites in 8 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.
Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 4, and was the 12th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Duke University · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,770 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 375 across the 24 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
36 studies in Hypercholesterolemia by Novartis: 6 open now, 10 under way, 5 of them phase 3. Of 26 finished, 10 (38%) have results posted.
Among the 36 studies in Hypercholesterolemia by Novartis, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2022, is one of 4 in phase 4, and was the 18th registered.
Novartis’s Hypercholesterolemia studies by the year they started, since 2002.
5 of the studies testing inclisiran in Hypercholesterolemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 24 studies testing inclisiran in Hypercholesterolemia, from their registry updates:
Among Novartis’s 36 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
This was a double-blind, placebo-controlled multicenter study in adult participants with very high or high cardiovascular risk who did not meet their individual LDL-C target despite being treated with their individual maximum tolerated dose (MTD) of a statin, and if applicable, further Lipid-Lowering Therapy (LLT).
The purpose of this study was to demonstrate the superiority of inclisiran compared to placebo, both on top of ongoing individually optimized LLT, on reaching a participant's LDL-C target (\< 55 mg/dL or \< 70 mg/dL, depending on the cardiovascular risk category), according to the 2019 ESC/EAS guidelines for the management of dyslipidemias as well as on patient-relevant safety, tolerability outcomes and quality of life.
Key Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
Participants categorized as very high or high CV risk, as defined below:
•Very high risk participants with at least one of the following: A. Documented Atherosclerotic Cardiovascular Disease (ASCVD) i) Acute Coronary Syndrome: Unstable angina or myocardial infarction ii) Stable angina iii) Unequivocally documented ASCVD upon prior imaging v) Stroke and (TIA) vi) Peripheral Artery Disease (PAD) B. Diabetes mellitus (DM) with target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), or at least ≥ 3 major risk factors, or early onset of Type 1 DM of long duration (> 20 years) C. A calculated SCORE2 ≥ 7.5% for age \< 50 years; SCORE2 ≥ 10% for age 50-69 years; SCORE2-OP ≥ 15% for age ≥ 70 years to estimate 10-year risk of fatal and non-fatal CVD D. Pre-existing diagnosis of heterozygous familial hypercholesterolemia (HeFH) with ASCVD or with another major risk factor.
OR
•High risk participants with at least one of the following: A. Markedly elevated single risk factors, in particular total cholesterol > 310 mg/dL, LDL-C > 190 mg/dL, or blood pressure ≥ 180/110 mmHg B. Pre-existing diagnosis of HeFH without other major risk factors C. DM without target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), with DM duration ≥ 10 years or other additional risk factor D. Moderate chronic kidney disease ( 30-59 mL/min/1.73m2) E. A calculated SCORE2 2.5 to \<7.5% for age under 50 years; SCORE2 5 to \<10% for age 50-69 years; SCORE2-OP 7.5 to \<15% for age ≥70 years to estimate 10-year risk of fatal and non-fatal CVD as defined by the cardiovascular risk categories in the 2019 ESC/EAS guideline (Mach et al 2020)
LDL-C levels:
Fasting triglyceride \< 400 mg/dL.
At Baseline:
Before randomization, despite being treated with the individual MTD of a statin for ≥ 30 days and, if applicable, with another LLT on top of statin (stable for ≥ 30 days),
Key Exclusion Criteria: Participants meeting any of the following criteria are not eligible for inclusion in this study.
Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while taking study treatment, which includes rosuvastatin, and for 5 days (= 5 times the terminal half-life of rosuvastatin) after stopping medication. Highly effective contraception methods include:
In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
Women are considered if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women are considered not of child bearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessments and she is considered not of child bearing potential.
If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the local ICF.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran sodium 300 mg s.c. + open label rosuvastatin Open label study treatment rosuvastatin: participants receive an individually optimized rosuvastatin therapy for reaching the individual LDL-C target and tolerability
Drug: Inclisiran Sodium
Corresponding placebo + open label rosuvastatin Open label study treatment rosuvastatin: participants receive an individually optimized rosuvastatin therapy for reaching the individual LDL-C target and tolerability
Drug: Placebo
Subcutaneously injected on Day 1, Day 90, and Day 270
Also known as: KJX839
Placebo to inclisiran 300 mg subcutaneously
Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL)
Number of participants achieving individual Low-density Lipoprotein Cholesterol (LDL-C) target (\< 55 mg/dL or \< 70 mg/dL) at Day 90. The individual LDL-C target of the participants was determined according to their most recent individual cardiovascular risk category. A larger proportion of participants indicates a superior outcome.
Time frame: Day 90
Relative Change From Baseline to Mean LDL-C Level Over the Double-blind Treatment Period
Relative (percentage) change from baseline in Low-density Lipoprotein Cholesterol (LDL-C) level averaged over the double-blind treatment period
Time frame: Baseline to Day 360
Number of Participants Experiencing at Least One Muscle-related Adverse Event From Day 1 to Day 360
The number of participants who experienced at least one muscle-related adverse event, defined as Standardized MedDRA Queries (SMQ) rhabdomyolysis / myopathy from Day 1 to Day 360. All muscle-related adverse events occurring between first dose of double-blind treatment and earliest date out of visit Day 360, death date and last contact date are considered.
Time frame: Day 1 to Day 360
Number of Participants Experiencing Self-reported Pain
Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain. The percentage of days with pain for each participant is calculated as number of days with pain divided by the total number of days where diary was completed, multiplied by 100. Diary data between the first dose of double-blind treatment up to the minimum of last contact date and Day 360 visit are considered.
Time frame: Day 1 to Day 360
Annualized Number of Days With Pain
Annualized rate refers to the estimated number of days with pain per year. Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain.
Time frame: Day 1 to Day 360
Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score Over the Double-blind Treatment Period
The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.
Time frame: Baseline to Day 360
Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score Over the Double-blind Treatment Period
The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.
Time frame: Baseline to Day 360
Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score From Baseline to Day 360.
The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain severity score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.
Time frame: Baseline to Day 360
Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score From Baseline to Day 360
The SF-BPI is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain interference score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.
Time frame: Baseline to Day 360
| Milestone | Inclisiran | Placebo |
|---|---|---|
| Started | 898 | 872 |
| Full analysis set (fas) | 898 | 872 |
| Safety set (saf) | 900 | 870 |
| Completed | 880 | 845 |
| Not completed | 18 | 27 |
| Withdrew: Subject decision | 8 | 15 |
| Withdrew: Death | 6 | 5 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Physician decision | 0 | 1 |
Number of participants achieving individual Low-density Lipoprotein Cholesterol (LDL-C) target (\< 55 mg/dL or \< 70 mg/dL) at Day 90. The individual LDL-C target of the participants was determined according to their most recent individual cardiovascular risk category. A larger proportion of participants indicates a superior outcome.
| Participants | Inclisiran | Placebo |
|---|---|---|
| Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL) | 752 | 266 |
Relative (percentage) change from baseline in Low-density Lipoprotein Cholesterol (LDL-C) level averaged over the double-blind treatment period
| percent change in LDL-C | Inclisiran | Placebo |
|---|---|---|
| Relative Change From Baseline to Mean LDL-C Level Over the Double-blind Treatment Period | -59.45 (-60.79 to -58.11) | -24.31 (-25.68 to -22.93) |
The number of participants who experienced at least one muscle-related adverse event, defined as Standardized MedDRA Queries (SMQ) rhabdomyolysis / myopathy from Day 1 to Day 360. All muscle-related adverse events occurring between first dose of double-blind treatment and earliest date out of visit Day 360, death date and last contact date are considered.
| Participants | Inclisiran | Placebo |
|---|---|---|
| Number of Participants Experiencing at Least One Muscle-related Adverse Event From Day 1 to Day 360 | 107 | 167 |
Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain. The percentage of days with pain for each participant is calculated as number of days with pain divided by the total number of days where diary was completed, multiplied by 100. Diary data between the first dose of double-blind treatment up to the minimum of last contact date and Day 360 visit are considered.
| Participants | Inclisiran | Placebo |
|---|---|---|
| Percentage of days with pain: 0% | 143 | 98 |
| Percentage of days with pain: >0-20% | 189 | 177 |
| Percentage of days with pain: >20-40% | 45 | 71 |
| Percentage of days with pain: >40-60% | 60 | 44 |
| Percentage of days with pain: >60-80% | 48 | 48 |
| Percentage of days with pain: >80% | 409 | 432 |
| Percentage of days with pain: Missing | 4 | 2 |
Annualized rate refers to the estimated number of days with pain per year. Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain.
| Days | Inclisiran | Placebo |
|---|---|---|
| Annualized Number of Days With Pain | 198.63 (180.46 to 218.62) | 214.51 (194.63 to 236.42) |
The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.
| score on a scale | Inclisiran | Placebo |
|---|---|---|
| Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score Over the Double-blind Treatment Period | -0.21 (-0.30 to -0.13) | -0.10 (-0.19 to -0.02) |
The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.
| score on a scale | Inclisiran | Placebo |
|---|---|---|
| Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score Over the Double-blind Treatment Period | -0.06 (-0.14 to 0.02) | 0.05 (-0.03 to 0.13) |
The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain severity score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.
| Participants | Inclisiran | Placebo |
|---|---|---|
| Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score From Baseline to Day 360. | 123 | 104 |
The SF-BPI is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain interference score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.
| Participants | Inclisiran | Placebo |
|---|---|---|
| Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score From Baseline to Day 360 | 87 | 70 |
Collected over Treatment-emergent adverse events were reported in the clinical database from first dose of study treatment until the study completion visit, up to a planned maximum duration of 360 days.. Non-serious events are listed at a 1.999% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran | 6/900 (0.7%) | 148/900 (16.4%) | 416/900 (46.2%) |
| Placebo | 5/870 (0.6%) | 148/870 (17%) | 462/870 (53.1%) |
| Total | 11/1,770 (0.6%) | 296/1,770 (16.7%) | 878/1,770 (49.6%) |
| Event | Inclisiran | Placebo | Total |
|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/900 | 12/870 | 16/1770 |
| Atrial fibrillationCardiac disorders | 12/900 | 5/870 | 17/1770 |
| Angina pectorisCardiac disorders | 5/900 | 9/870 | 14/1770 |
| Angina unstableCardiac disorders | 7/900 | 2/870 | 9/1770 |
| Coronary artery diseaseCardiac disorders | 7/900 | 5/870 | 12/1770 |
| Peripheral arterial occlusive diseaseVascular disorders | 7/900 | 6/870 | 13/1770 |
| PneumoniaInfections and infestations | 6/900 | 4/870 | 10/1770 |
| Chest painGeneral disorders and administration site conditions | 5/900 | 1/870 | 6/1770 |
| Ischaemic strokeNervous system disorders | 1/900 | 4/870 | 5/1770 |
| Acute kidney injuryRenal and urinary disorders | 2/900 | 4/870 | 6/1770 |
| Event | Inclisiran | Placebo | Total |
|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 49/900 | 82/870 | 131/1770 |
| NasopharyngitisInfections and infestations | 74/900 | 79/870 | 153/1770 |
| COVID-19Infections and infestations | 55/900 | 55/870 | 110/1770 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 55/900 | 49/870 | 104/1770 |
| Back painMusculoskeletal and connective tissue disorders | 52/900 | 46/870 | 98/1770 |
| DiarrhoeaGastrointestinal disorders | 28/900 | 50/870 | 78/1770 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 27/900 | 48/870 | 75/1770 |
| ConstipationGastrointestinal disorders | 19/900 | 43/870 | 62/1770 |
| NauseaGastrointestinal disorders | 16/900 | 41/870 | 57/1770 |
| HypertensionVascular disorders | 42/900 | 32/870 | 74/1770 |
Baseline Characteristics are based on the Full analysis set (FAS)
| Age, Categorical(Participants) | Inclisiran | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 462 | 443 | 905 |
| >=65 years | 436 | 429 | 865 |
| Age, Continuous(years) | Inclisiran | Placebo | Total |
|---|---|---|---|
| Mean | 63.8 ± 9.69 | 63.7 ± 9.99 | 63.7 ± 9.84 |
| Sex: Female, Male(Participants) | Inclisiran | Placebo | Total |
|---|---|---|---|
| Female | 273 | 262 | 535 |
| Male | 625 | 610 | 1235 |
| Race/Ethnicity, Customized(Participants) | Inclisiran | Placebo | Total |
|---|---|---|---|
| White | 870 | 845 | 1715 |
| Black or African American | 1 | 4 | 5 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| American Indian or Alaska Native | 0 | 2 | 2 |
| Unknown | 2 | 2 | 4 |
| Not Reported | 22 | 17 | 39 |
Showing the first 100 of 136 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2022 to primary completion in Jun 2024, 26 months.
Results were first posted in Apr 2026, 1 year 10 months after primary completion.
Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran